| 51 |
15367711 | Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. | 2004 Sep |
1 |
| 52 |
12660450 | Synergism of Fas-mediated apoptosis and tumor necrosis factor on adriamycin cytotoxicity to transitional cell carcinoma. | 2003 |
3 |
| 53 |
12850194 | Current uses of isolated limb perfusion in the clinic and a model system for new strategies. | 2003 Jul |
2 |
| 54 |
12908082 | Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells. | 2003 Nov |
2 |
| 55 |
13679856 | ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. | 2003 Sep 18 |
1 |
| 56 |
11389822 | Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. | 2001 Jul |
1 |
| 57 |
11572767 | Augmented adriamycin sensitivity in cells transduced with an antisense tumor necrosis factor gene is mediated by caspase-3 downstream from reactive oxygen species. | 2001 Sep |
3 |
| 58 |
10880020 | Mdr1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors. | 2000 Jun |
1 |
| 59 |
11131649 | An overview on the use of TNF-alpha: our experience with regional administration and developments towards new opportunities for systemic application. | 2000 Sep- Oct |
1 |
| 60 |
9935184 | JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF-alpha. | 1999 Jan 29 |
1 |
| 61 |
9639400 | Enhanced sensitivity to tumor necrosis factor-alpha in doxorubicin-resistant tumor cell lines due to down-regulated c-erbB2. | 1998 Jul 3 |
2 |
| 62 |
9711910 | Endogenous tumor necrosis factor and doxorubicin sensitivity in leukemic patients. | 1998 Aug |
1 |
| 63 |
9713511 | The apoptotic signaling of TNF-alpha in multidrug resistant Friend leukemia cells. | 1998 Jul-Aug |
4 |
| 64 |
9116291 | Endogenous tumor necrosis factor as a predictor of doxorubicin sensitivity in leukemic patients. | 1997 Apr 1 |
3 |
| 65 |
8856983 | Tumor necrosis factor and lymphotoxin: protection against oxidative stress through induction of MnSOD. | 1996 |
1 |
| 66 |
8858979 | Endogenous tumor necrosis factor enhances topoisomerase II inhibitors activity in human ovarian cancer cell lines. | 1996 Oct |
1 |
| 67 |
8899800 | Endogenous tumor necrosis factor inhibits the cytotoxicity of exogenous tumor necrosis factor and adriamycin in pancreatic carcinoma cells. | 1996 Nov |
4 |
| 68 |
7775261 | Reversal of tumor necrosis factor resistance in tumor cells by adriamycin via suppression of intracellular resistance factors. | 1995 Apr |
7 |
| 69 |
7790119 | Gene transfer of human TNF alpha into glioblastoma cells permits modulation of mdr1 expression and potentiation of chemosensitivity. | 1995 Jun 9 |
1 |
| 70 |
9384669 | Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha. | 1995 Jun |
2 |
| 71 |
7905787 | Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression. | 1994 Feb 1 |
4 |
| 72 |
7914182 | Endogenous tumor necrosis factor functions as a resistant factor against adriamycin. | 1994 Aug 1 |
3 |
| 73 |
8283917 | Tumor necrosis factor induces doxorubicin resistance to lung cancer cells in vitro. | 1994 Jan |
2 |
| 74 |
7684321 | Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. | 1993 Jun 1 |
1 |
| 75 |
8317554 | Age-dependent basal level and induction capacity of copper-zinc and manganese superoxide dismutase and other scavenging enzyme activities in leukocytes from young and elderly adults. | 1993 Jul |
1 |
| 76 |
8428693 | Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype. | 1993 Feb |
2 |
| 77 |
1418895 | Tumor necrosis factor and chemotherapeutic agents. Potentiation of cytotoxicity with interferon gamma. | 1992 Nov |
2 |
| 78 |
1651105 | Doxorubicin-induced cross-resistance to tumor necrosis factor (TNF) related to differential TNF processing. | 1991 Jun |
5 |
| 79 |
2166714 | Effects of tumor necrosis factor, alone or in combination with topoisomerase-II-targeted drugs, on human lung cancer cell lines. | 1990 Aug 15 |
1 |
| 80 |
2227544 | Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells. | 1990 Sep |
1 |
| 81 |
2249897 | Augmentation for intratumoral accumulation and anti-tumor activity of liposome-encapsulated adriamycin by tumor necrosis factor-alpha in mice. | 1990 Dec 15 |
1 |
| 82 |
2362291 | Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines. | 1990 Jul 18 |
1 |
| 83 |
2363856 | Augmentation of the effect of doxorubicin with low-dose tumor necrosis factor in experimental liver metastasis. | 1990 Jun |
4 |
| 84 |
2688030 | Tumor necrosis factors. | 1989 |
1 |
| 85 |
2838845 | Specificity of tumor necrosis factor toxicity for human mammary carcinomas relative to normal mammary epithelium and correlation with response to doxorubicin. | 1988 Jul |
3 |
| 86 |
3291772 | [Anti-tumor effect of human recombinant TNF]. | 1988 Apr |
3 |